某三级医疗保健中心老年人处方药物与新冠肺炎治疗研究药物可能相互作用的评价

IF 0.8 Q4 PHARMACOLOGY & PHARMACY

Journal of Research in Pharmacy Practice Pub Date : 2021-01-11 eCollection Date: 2020-10-01 DOI:10.4103/jrpp.JRPP_20_107

Yogendra Keche, Nitin Gaikwad, Suryaprakash Dhaneria, Apoorva Joshi

{"title":"某三级医疗保健中心老年人处方药物与新冠肺炎治疗研究药物可能相互作用的评价","authors":"Yogendra Keche, Nitin Gaikwad, Suryaprakash Dhaneria, Apoorva Joshi","doi":"10.4103/jrpp.JRPP_20_107","DOIUrl":null,"url":null,"abstract":"Objective: Earlier identifying drug interactions may help in risk reduction in elderly patients.Methods: Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug interaction had been checked from Stockley's Drug Interaction 2019 and Martindale the Complete Drug Reference 2017 and standard reference books of Pharmacology.Findings: Different types of drugs prescribed in the elderly were 260 and out of which 68 (26.36%) were in the category of fixed-dose combinations. Around 150 (70.75%) elderly patients were having one or more associated comorbidities. Thirty-five drugs prescribed to elderly had been found to cause drug interaction with investigational drugs for COVID-19. Possible drug interactions are mediated through CYP3A4 (eighteen patients), CYP2D6 (seven patients) isoenzymes, or P glycoproteins transporters (three patients).Conclusion: Possible drug interactions predicted in this study suggested need for modification of dose of drug or watchfulness for adverse effects. If these drug interactions are considered beforehand, complications can be prevented on account of these drug interactions in elderly who are suffering from COVID-19.","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"9 4","pages":"212-217"},"PeriodicalIF":0.8000,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/23/JRPP-9-212.PMC8067896.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.\",\"authors\":\"Yogendra Keche, Nitin Gaikwad, Suryaprakash Dhaneria, Apoorva Joshi\",\"doi\":\"10.4103/jrpp.JRPP_20_107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Earlier identifying drug interactions may help in risk reduction in elderly patients.Methods: Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug interaction had been checked from Stockley's Drug Interaction 2019 and Martindale the Complete Drug Reference 2017 and standard reference books of Pharmacology.Findings: Different types of drugs prescribed in the elderly were 260 and out of which 68 (26.36%) were in the category of fixed-dose combinations. Around 150 (70.75%) elderly patients were having one or more associated comorbidities. Thirty-five drugs prescribed to elderly had been found to cause drug interaction with investigational drugs for COVID-19. Possible drug interactions are mediated through CYP3A4 (eighteen patients), CYP2D6 (seven patients) isoenzymes, or P glycoproteins transporters (three patients).Conclusion: Possible drug interactions predicted in this study suggested need for modification of dose of drug or watchfulness for adverse effects. If these drug interactions are considered beforehand, complications can be prevented on account of these drug interactions in elderly who are suffering from COVID-19.\",\"PeriodicalId\":17158,\"journal\":{\"name\":\"Journal of Research in Pharmacy Practice\",\"volume\":\"9 4\",\"pages\":\"212-217\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2021-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/23/JRPP-9-212.PMC8067896.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Research in Pharmacy Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jrpp.JRPP_20_107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.JRPP_20_107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的:早期识别药物相互作用可能有助于降低老年患者的风险。方法:分析三级卫生保健中心212例老年患者的药物处方资料，分析其与治疗新冠肺炎的研究药物可能存在的药物相互作用。药物相互作用已从Stockley的《药物相互作用2019》和Martindale的《药物完全参考2017》和药理学标准参考书中进行了检查。结果:老年人处方不同类型药物260种，其中固定剂量联合用药68种，占26.36%;约150例(70.75%)老年患者有一种或多种相关合并症。已发现35种老年人处方药物与新冠肺炎研究药物相互作用。可能的药物相互作用是通过CYP3A4(18例)、CYP2D6(7例)同工酶或P糖蛋白转运蛋白(3例)介导的。结论:本研究预测可能的药物相互作用提示需要调整药物剂量或注意不良反应。如果事先考虑到这些药物相互作用，则可预防感染COVID-19的老年人因这些药物相互作用而出现并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.

Objective: Earlier identifying drug interactions may help in risk reduction in elderly patients.

Methods: Drug prescription data of 212 elderly patients of tertiary health care center had been analyzed for possible drug interactions with investigational drugs for COVID-19 treatment. Drug interaction had been checked from Stockley's Drug Interaction 2019 and Martindale the Complete Drug Reference 2017 and standard reference books of Pharmacology.

Findings: Different types of drugs prescribed in the elderly were 260 and out of which 68 (26.36%) were in the category of fixed-dose combinations. Around 150 (70.75%) elderly patients were having one or more associated comorbidities. Thirty-five drugs prescribed to elderly had been found to cause drug interaction with investigational drugs for COVID-19. Possible drug interactions are mediated through CYP3A4 (eighteen patients), CYP2D6 (seven patients) isoenzymes, or P glycoproteins transporters (three patients).

Conclusion: Possible drug interactions predicted in this study suggested need for modification of dose of drug or watchfulness for adverse effects. If these drug interactions are considered beforehand, complications can be prevented on account of these drug interactions in elderly who are suffering from COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

21 weeks

期刊介绍： The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.